Quick Answer
NRX Pharmaceuticals, Inc. reported Net Income of -$28.62 million for fiscal year 2025.
NRX Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$28.62M | -13.9% |
| 2024 | -$25.13M | +16.7% |
| 2023 | -$30.15M | +24.2% |
| 2022 | -$39.75M | +57.3% |
| 2021 | -$93.06M | -79.7% |
| 2020 | -$51.78M | -12777.2% |
| 2019 | $408.4K | +517.9% |
| 2018 | $66.1K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$5.89M | -262.9% | +66.5% |
| June 30, 2025 | -$17.58M | -122.6% | -219.0% |
| March 31, 2025 | -$5.51M | +15.6% | -239.6% |
| September 30, 2024 | -$1.62M | +73.2% | +79.4% |
| June 30, 2024 | -$7.90M | +9.4% | -21.0% |
| March 31, 2024 | -$6.53M | -18.4% | -7.7% |
| September 30, 2023 | -$6.06M | +33.3% | +30.5% |
| June 30, 2023 | -$8.72M | -24.8% | -58.1% |
- NRX Pharmaceuticals, Inc. showed a decrease of -13.9% in Net Income compared to the prior fiscal year.
- Over the 2018–2025 period, NRX Pharmaceuticals, Inc.’s net income has declined by 43400.4% (from $66.1 thousand to -$28.62 million).
- The most recent figure is from NRX Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: